Vibativ (Telavancin HCl) Patent Expiration, LOE Window & CMS Spending
Vibativ (Telavancin HCl) by Apotex: FDA Orange Book core substance LOE 2027-01-01, 0 AB generics, $828K 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Apotex |
| FDA Application & Pathway | N022110 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2027-01-01 |
| Last Listed Patent or Exclusivity Date | 2027-01-01 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $828K |
| 2024 Medicare Part D Spend | $553K |
| 2024 Medicaid Spend | $275K |
| Reported Wholesale Price Change (CA SB 17) | 7 WAC filings (max 21.8% 2-yr change) |